Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TAF1 | P21675 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322031 | 0.86 | KDR (0.43) | EGFRERBB2FLT1KDRCDK2 | |
| SCHEMBL6329267 | 0.85 | KDR (0.51) | EGFRERBB2FLT1KDRCDK2 | |
| SCHEMBL6323735 | 0.85 | KDR (0.47) | EGFRFLT1KDRCDK2RET | |
| SCHEMBL6321962 | 0.83 | KDR (0.41) | EGFRERBB2FLT1KDRCDK2 | |
| SCHEMBL6321270 | 0.82 | EGFR (0.52) | EGFRKDRCDK2PDGFRBFLT3 | |
| SCHEMBL6321268 | 0.82 | EGFR (0.52) | EGFRKDRCDK2PDGFRBFLT3 | |
| SCHEMBL6323471 | 0.81 | KDR (0.39) | EGFRERBB2FLT1KDRCDK2 | |
| SCHEMBL6324029 | 0.80 | EGFR (0.51) | EGFRFLT1KDRCDK2RET | |
| SCHEMBL6324032 | 0.80 | EGFR (0.51) | EGFRFLT1KDRCDK2RET | |
| SCHEMBL6320423 | 0.80 | KDR (0.44) | EGFRERBB2FLT1KDRCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | EGFR 367/4885ERBB2 28/4885FLT1 1811/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | EGFR 367/4885ERBB2 28/4885FLT1 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.